Work

Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma

Year: 2020

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-020-00945-y

Authors: Bradley A. McGregor, Michael Gordon, Ronan Flippot, Neeraj Agarwal, Saby George, David I. Quinn, Mark Rogalski, Thomas Hawthorne, Tibor Keler, Toni K. Choueiri

Institutions: Dana-Farber Cancer Institute, HonorHealth, University of Utah, Huntsman Cancer Institute, Roswell Park Comprehensive Cancer Center, USC Norris Comprehensive Cancer Center, Celldex Therapeutics (United States), Dana-Farber/Harvard Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Celldex Therapeutics, National Cancer Institute

Awards: G8231620523, University of Southern California Norris Comprehensive Cancer Center Support Grant (CCSG)

OpenAlex ID: W3029599698

FWCI: 2.828

Cites: 29

Cited by: 44

Related to: 10